Orchid Pharma signs Russia deal for Exblifep in 2026

Deal highlights: exclusive rights for Russia

Orchid Pharma has signed an exclusive licensing and supply agreement with Russia’s Pharmasyntez JSC to commercialise Exblifep in Russia. The arrangement covers the registration and commercialisation of Exblifep, subject to regulatory approval by the Ministry of Health of the Russian Federation. Under the agreement structure outlined by the company, Pharmasyntez will hold exclusive commercial rights in Russia. Orchid will supply the finished dosage form for the market. The company framed the partnership as a commercial step in a market with significant hospital procurement volumes. Orchid also indicated the deal reflects unmet clinical need in severe hospital infections.

What Exblifep is used for

Exblifep is a novel combination antibiotic consisting of cefepime and enmetazobactam. Orchid said the product is intended for the treatment of complicated urinary tract infections (cUTI). It is also indicated for hospital-acquired and ventilator-associated bacterial pneumonia (HAP/VAP) caused by Gram negative bacterial pathogens, subject to local approvals. The company described Exblifep as a carbapenem-sparing option. It positioned the therapy as addressing challenges linked to ESBL-producing Gram-negative bacteria in serious hospital infections. These infections are a key concern in inpatient settings where resistant pathogens can limit treatment options.

Regulatory and guideline status

Orchid stated that Exblifep is approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The company also said it is included in IDSA and EUCAST treatment guidelines. Orchid highlighted that this is the first new chemical entity originating from an Indian pharmaceutical company to receive approvals from both the FDA and EMA. In Russia, the commercial rollout remains contingent on regulatory clearance from the country’s health ministry. The agreement’s next operational steps therefore depend on local registration timelines and related review processes.

What each partner will do

The agreement assigns Pharmasyntez the responsibility to register and commercialise Exblifep in Russia. Orchid’s role is to supply the finished dosage form, aligning the partnership around a licensing plus supply model. This structure allows Orchid to participate in the market through product supply while the local partner manages on-ground commercial execution. The exclusivity clause means Pharmasyntez will be the sole party with rights to register and sell Exblifep in Russia under this agreement. Orchid has not provided additional commercial terms in the information shared, beyond the headline opportunity estimate and the role split.

Opportunity size Orchid cited

Orchid pegged the partnership as a potential opportunity of approximately USD 178 million over the first 10 years. The company linked this estimate to the scale of unmet clinical need and hospital procurement volumes in Russia. The figure is presented as an opportunity estimate rather than booked revenue, and would be dependent on approvals and execution. It also implies a long-duration commercial plan rather than a one-time milestone event. Given that hospital antibiotics can be driven by tenders and institutional buying, volumes and timing can vary based on procurement cycles.

How the event fits Orchid’s broader licensing strategy

Separately, Orchid said it is in advanced discussions to out-license its novel antibiotic enmetazobactam in the United States. The company indicated that talks with potential partners are at an advanced stage, with a deal likely to be finalised in the near term. It also noted that, beyond the US, it is negotiating licensing agreements across Japan, Russia, Latin America, and Southeast Asia, with discussions ranging from term sheets to definitive agreements. Orchid said it expects at least half of these partnerships to be signed over the next few quarters. In India, Orchid has partnered with Cipla to distribute the drug.

Recent commercial progress outside Russia

Orchid reported early commercial launches of Exblifep in Spain, Italy, the UAE, and Kuwait. It also stated that sales in Europe were up over 200% on a small base. Management commentary pointed to ongoing licensing discussions in more than 10 countries and suggested that launch and agreement announcements could become more frequent as negotiations progress. In parallel, Orchid referenced a binding term sheet signed for one emerging market and a nonbinding term sheet in a major regulated market. The company also said it was in advanced discussions with three to four large markets.

Financial context: sales pressure in antibiotics

Orchid disclosed that sales fell 5% year-on-year in Q3 to INR 207 crore. For the nine-month period, sales were INR 574 crore versus INR 684 crore last year, a decline of 16%. The company attributed the drop to sustained pressure in the global antibiotics market. It also said both price and quantity in the oral segment declined over nine months, citing about 12% price erosion and 10% quantity erosion. Orchid described weakness as industry-wide, especially in regulated markets, and noted a notable drop in sales from Russia. At the same time, it said volumes improved sequentially from the previous quarter.

Background: the molecule’s ownership and repositioning

Orchid said it invented enmetazobactam but initially partnered for commercialisation. In 2013, the company out-licensed the molecule to Allecra Therapeutics to facilitate global clinical trials. It later executed a strategic shift in October 2025 by reacquiring 100% of the global rights and assets of Allecra Therapeutics. Orchid described this move as changing its role from a royalty-earning partner to the sole proprietor of an FDA-approved drug. The company said the reacquisition brought intellectual property back under Indian ownership. It also stated that it now controls the global licensing and distribution strategy across the United States, Europe, and emerging markets.

Pipeline and upcoming milestones mentioned by the company

Beyond Exblifep, Orchid said key pipeline products such as Teflaro and Avycaz are nearing U.S. filings, with partner agreements expected soon. It also referenced ongoing regulatory work for ceftolozane/tazobactam. Orchid said it is addressing FDA observations for ceftazidime/avibactam. For cefiderocol, it stated that a formulation launch in India is targeted for December 2026, and it hopes for a clinical trial waiver. The company also reiterated plans to expand Exblifep into multiple international markets.

Key facts table

Market impact and why the Russia deal matters

For Orchid, the Russia agreement adds a defined commercial pathway for Exblifep in a market it described as having significant hospital procurement volumes. The company has also acknowledged Russia as an area where its broader antibiotics business saw a notable drop in sales, making the new Exblifep channel relevant in the context of regional performance. However, near-term outcomes depend on regulatory approval in Russia and on the timing of registration and procurement. The deal also fits Orchid’s stated approach of building multiple country-level partnerships for the molecule, including negotiations across Japan, Latin America, and Southeast Asia and advanced talks for the United States.

Conclusion

Orchid Pharma’s exclusive licensing and supply agreement with Pharmasyntez sets up a route to commercialise Exblifep in Russia, with Orchid supplying the finished product and the local partner handling registration and sales. The company has estimated a potential USD 178 million opportunity over 10 years, subject to Russian regulatory approval and market execution. Alongside this, Orchid has reported early launches in select European and Middle East markets and continues to pursue additional licensing deals globally. The next key milestones remain regulatory progress in Russia and the company’s broader set of partnership announcements, including its stated advanced-stage US licensing discussions.